Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009 ...

Agios Pharmaceuticals (AGIO) shares soared 17.7% in the last trading session to close at $44.01. The move was backed by solid ...

New research finds that birds can use lactate, often thought of as a metabolic waste product, as a cellular fuel that aids in ...

Agios Pharmaceuticals shares rose Tuesday after the U.S. Food and Drug Administration granted priority review to the company's supplemental new drug application for mitapivat to treat sickle cell ...

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...

Fibromyalgia is a painful syndrome that also affects the psyche. Fortunately, improving the gut microbiome can significantly ...

For doctors around the world, Alessandro is almost a miracle: he is the first patient affected by an extremely rare metabolic ...

For millennia, thick, healthy hair has symbolized both masculine virility and feminine appeal. So when hair thins or disappears altogether—which happens to approximately 80 percent of men and 50 ...

Shares of Agios Pharmaceuticals (AGIO) traded higher in the premarket on Tuesday after the U.S. FDA granted priority review for its marketing application seeking a label expansion for its lead product ...

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...